Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

The latest price target for Passage Bio (NASDAQ:PASG) was reported by Chardan Capital on June 24, 2025. The analyst firm set a price target for $6.00 expecting PASG to rise to within 12 months (a ...

Passage Bio (PASG) announced new interim results from the first six patients in its Phase 1/2 study for PBGM01 targeted at GM1 Gangliosidosis ((GM1)), Read full story here.

Fintel reports that on September 3, 2024, Rodman & Renshaw initiated coverage of Passage Bio (NasdaqGS:PASG) with a Buy recommendation. Analyst Price Forecast Suggests 940.03% Upside As of August ...

For PASG, shares are up 24.26% over the past week while the Zacks Medical - Biomedical and Genetics industry is up 3.78% over the same time period.

The Presidential Anti-Smuggling Group (PASG) denied yesterday that it has linked Liberal Party standard-bearer Benigno “Noynoy” Aquino III and Quezon Gov. Rafael Nantes to the reported illegal ...

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

Passage Bio, Inc. (PASG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...